BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rosenbaum MW, Gonzalez RS. Targeted therapy for upper gastrointestinal tract cancer: current and future prospects. Histopathology 2021;78:148-61. [PMID: 33382497 DOI: 10.1111/his.14244] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Ding YN, Xue M, Tang QS, Wang LJ, Ding HY, Li H, Gao CC, Yu WP. Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges. World J Gastroenterol 2022; 28(37): 5403-5419 [DOI: 10.3748/wjg.v28.i37.5403] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Ogden S, Ahmed I, Fullwood P, Francavilla C, Sharrocks AD, the OCCAMS consortium. Oncogenic ERRB2 signals through the AP-1 transcription factor to control mesenchymal-like properties of oesophageal adenocarcinoma.. [DOI: 10.1101/2022.08.14.503893] [Reference Citation Analysis]
3 Zhao C, Rong Z, Ding J, Wang L, Wang B, Ding L, Meng L, Meng X, Wang F, Yang Z, Shou C, Zhu H. Targeting Claudin 18.2 Using a Highly Specific Antibody Enables Cancer Diagnosis and Guided Surgery. Mol Pharm 2022. [PMID: 35344359 DOI: 10.1021/acs.molpharmaceut.1c00947] [Reference Citation Analysis]
4 Rosenbaum MW, Gonzalez RS. Immunohistochemistry as predictive and prognostic markers for gastrointestinal malignancies. Semin Diagn Pathol 2021:S0740-2570(21)00078-2. [PMID: 34740486 DOI: 10.1053/j.semdp.2021.10.003] [Reference Citation Analysis]
5 Bolger JC, Donohoe CL, Lowery M, Reynolds JV. Advances in the curative management of oesophageal cancer. Br J Cancer 2021. [PMID: 34675397 DOI: 10.1038/s41416-021-01485-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
6 Jiang Q, Chen L, Chen H, Tang Z, Liu F, Sun Y. Integrated Analysis of Stemness-Related LncRNAs Helps Predict the Immunotherapy Responsiveness of Gastric Cancer Patients. Front Cell Dev Biol 2021;9:739509. [PMID: 34589496 DOI: 10.3389/fcell.2021.739509] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jiang Q, Chen H, Tang Z, Sun J, Ruan Y, Liu F, Sun Y. Stemness-related LncRNA pair signature for predicting therapy response in gastric cancer. BMC Cancer 2021;21:1067. [PMID: 34587919 DOI: 10.1186/s12885-021-08798-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
8 Xue S, Ma M, Bei S, Li F, Wu C, Li H, Hu Y, Zhang X, Qian Y, Qin Z, Jiang J, Feng L. Identification and Validation of the Immune Regulator CXCR4 as a Novel Promising Target for Gastric Cancer. Front Immunol 2021;12:702615. [PMID: 34322132 DOI: 10.3389/fimmu.2021.702615] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
9 Kang MH, Eyun SI, Park YY. Estrogen-related receptor-gamma influences Helicobacter pylori infection by regulating TFF1 in gastric cancer. Biochem Biophys Res Commun 2021;563:15-22. [PMID: 34058470 DOI: 10.1016/j.bbrc.2021.05.076] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]